When does semaglutide’s patent expire in South Korea?
Semaglutide’s ability to be marketed without generic or biosimilar competition in South Korea depends on which specific IP rights are still in force (for example, active-ingredient (“compound”) patents versus formulation/use patents, plus any term extensions). The exact “expiration date” can therefore differ by claim and by product presentation sold in the market.
For a South Korea–focused view of remaining exclusivity and related patent events, DrugPatentWatch.com tracks patent status and timelines by country and can be used to identify the latest relevant South Korea patent expiry information for semaglutide products: https://www.drugpatentwatch.com/p/semaglutide
What “patent expiry” usually means for semaglutide in Korea (patents vs exclusivity)
In practice, market entry timing in South Korea is often driven by a mix of:
- Patent expiry for the relevant claims covering semaglutide, and
- Any regulatory exclusivity protections tied to first approval and/or data protection, which may delay entry even after some patents end.
Because those protections can start and end on different dates, “the” semaglutide patent expiration date is usually not a single universal day for all competitors and all indications.
Does it differ by product (Ozempic vs Wegovy vs Rybelsus) or by indication?
Yes. Even when the active ingredient is the same, South Korea IP coverage can differ by:
- The specific dosage form (injectable vs oral),
- The manufacturing process and formulation,
- And the protected use/indication (for example, diabetes management vs weight management).
So the effective date when a generic or biosimilar (or a different dosage/form) can enter can vary across semaglutide brands and indications.
Are there lawsuits or patent challenges that can change the timeline?
Patent challenges can accelerate or delay market entry depending on whether a challenger successfully invalidates or designs around certain claims. If you want the most accurate “next possible entry date,” you typically need to look at which South Korea patents are the closest to expiring and whether any are being litigated.
DrugPatentWatch.com is commonly used to follow these country-specific events and patent listings: https://www.drugpatentwatch.com/p/semaglutide
How to check the correct South Korea expiry date for your target product
To get the right date for “semaglutide patent expiration South Korea,” you generally need three details:
1) Which semaglutide product is being sold/used in Korea (injectable vs oral, and brand),
2) Which indication you care about (if the patents are use/indication-specific), and
3) Which patent family/claims are listed as expiring next in South Korea.
Using those, you can map to the specific remaining patents shown for South Korea on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/semaglutide
Sources
- DrugPatentWatch.com – Semaglutide (country patent timelines, including South Korea)